GLP-1 receptor agonists have created the most commercially significant new drug class in pharmaceutical history. Eli Lilly’s Mounjaro and Zepbound and Novo Nordisk’s Ozempic and Wegovy generated combined revenues exceeding $45 billion in 2025. Eli Lilly reported 45% full year revenue growth in 2025 driven by these two products, projecting $80-83 billion in revenues for 2026.
The GLP-1 story is far from complete. The cardiovascular benefits of semaglutide and tirzepatide are expanding the eligible patient population far beyond obesity and type 2 diabetes into cardiovascular risk reduction, heart failure, chronic kidney disease, obstructive sleep apnea, and neurological indications. Eli Lilly submitted orforglipron — an oral GLP-1 receptor agonist — for regulatory approval in the U.S. and more than 40 countries in 2025.
Topics Covered
• GLP-1 Commercial Landscape
• Oral GLP-1 Formulations
• Next-Generation Dual and Triple Agonists
• Cardiovascular Indications
• Indication Expansion
• Competitive Entry
• Pricing and Access
Table of Contents
1. Executive Summary
2. Market Overview
3. GLP-1 Commercial Landscape
4. Oral GLP-1 Formulations
5. Next-Generation Dual and Triple Agonists
6. Cardiovascular Indications
7. Indication Expansion
8. Competitive Entry
9. Pricing and Access
10. Competitive Landscape
11. Regional Market Analysis
12. Strategic Conclusions and Recommendations
13. Appendix
List of Tables
Table 1. Market Overview and Leading Products 2025
Table 2. Competitive Landscape by Sub-Segment 2025
Table 3-8. Topic-Specific Analysis Tables
Table 3. Leading Companies — Portfolio and Pipeline Assessment 2025
Table 4. M&A and Licensing Activity 2023-2025
Table 5. Regional Market Analysis
Table 6. Key Risks and Mitigation Strategies
Companies Profiled
Novo Nordisk
Eli Lilly
Sanofi
AstraZeneca
Pfizer
Roche
Viking Therapeutics
Structure Therapeutics
